3 terminated, 2 completed. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Completed 2 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Handok Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients CTX-009 (ABL001), Paclitaxel, Irinotecan - P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | Handok Inc. | 41 | 2020-06-22 | 2025-01-27 |
| Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension Irbesartan/Amlodipine - Essential Hypertension | Phase 2 | Completed | Handok Inc. | 440 | 2020-05-21 | 2022-06-30 |
| HL2351 CAPS Phase II Study HL2351 - Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase 2 | Terminated | Handok Inc. | 8 | 2015-10-01 | 2017-01-04 |
| Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) EO9 (Apaziquone), Placebo - Bladder Cancer | Phase 2 / Phase 3 | Terminated | Nippon Kayaku Co., Ltd. | 51 | 2011-11-01 | 2017-03-29 |
| Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female alfuzosin hydrochloride XL 10mg, Placebo - Voiding Dysfunction | Phase 2 | Completed | Samsung Medical Center | 190 | 2008-06-01 | 2013-06-10 |
Cryopyrin-Associated Periodic Syndromes (1) · Essential Hypertension (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1)
Amlodipine (1) · Irbesartan (1) · Irinotecan (1) · Paclitaxel (1) · alfuzosin (1) · apaziquone (1) · asciminib (1)
South Korea (5) · Japan (1)
Kyu-Sung Lee, Ph.D (1) · Woo Ick Jang, M.D., Ph.D. (1) · Yoshihiro Nambu, M.D., Ph.D. (1)